UCB SA (UNC.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:UNC - BE0003739530 - Common Stock
255.7 EUR
-3.9 (-1.5%)
Taking everything into account, UNC scores 6 out of 10 in our fundamental rating. UNC was compared to 54 industry peers in the Pharmaceuticals industry. UNC has only an average score on both its financial health and profitability. UNC is valued quite expensive, but it does show an excellent growth. These ratings would make UNC suitable for growth investing!
1. Profitability
1.1 Basic Checks
- In the past year UNC was profitable.
- UNC had a positive operating cash flow in the past year.
- UNC had positive earnings in each of the past 5 years.
- Each year in the past 5 years UNC had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 7.75%, UNC is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
- UNC has a Return On Equity (13.76%) which is in line with its industry peers.
- The Return On Invested Capital of UNC (11.63%) is comparable to the rest of the industry.
- UNC had an Average Return On Invested Capital over the past 3 years of 4.35%. This is significantly below the industry average of 13.93%.
- The 3 year average ROIC (4.35%) for UNC is below the current ROIC(11.63%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROIC | 11.63% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
- UNC's Profit Margin of 19.45% is fine compared to the rest of the industry. UNC outperforms 75.93% of its industry peers.
- UNC's Profit Margin has been stable in the last couple of years.
- With a decent Operating Margin value of 26.58%, UNC is doing good in the industry, outperforming 68.52% of the companies in the same industry.
- UNC's Operating Margin has declined in the last couple of years.
- With a decent Gross Margin value of 73.38%, UNC is doing good in the industry, outperforming 64.81% of the companies in the same industry.
- In the last couple of years the Gross Margin of UNC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
- UNC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for UNC remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, UNC has more shares outstanding
- The debt/assets ratio for UNC has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 5.42 indicates that UNC is not in any danger for bankruptcy at the moment.
- The Altman-Z score of UNC (5.42) is better than 74.07% of its industry peers.
- The Debt to FCF ratio of UNC is 2.43, which is a good value as it means it would take UNC, 2.43 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of UNC (2.43) is better than 81.48% of its industry peers.
- A Debt/Equity ratio of 0.29 indicates that UNC is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.29, UNC is in the better half of the industry, outperforming 70.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 5.42 |
ROIC/WACC1.5
WACC7.76%
2.3 Liquidity
- UNC has a Current Ratio of 1.35. This is a normal value and indicates that UNC is financially healthy and should not expect problems in meeting its short term obligations.
- UNC has a Current ratio of 1.35. This is comparable to the rest of the industry: UNC outperforms 53.70% of its industry peers.
- UNC has a Quick Ratio of 1.01. This is a normal value and indicates that UNC is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of UNC (1.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
- UNC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.41%, which is quite impressive.
- UNC shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.86% yearly.
- Looking at the last year, UNC shows a very strong growth in Revenue. The Revenue has grown by 25.56%.
- UNC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.60% yearly.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
3.2 Future
- Based on estimates for the next years, UNC will show a very strong growth in Earnings Per Share. The EPS will grow by 28.44% on average per year.
- UNC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.09% yearly.
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y28.44%
Revenue Next Year25.37%
Revenue Next 2Y19.85%
Revenue Next 3Y17.72%
Revenue Next 5Y15.09%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 39.83, the valuation of UNC can be described as expensive.
- Based on the Price/Earnings ratio, UNC is valued a bit more expensive than 61.11% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 26.94. UNC is valued slightly more expensive when compared to this.
- Based on the Price/Forward Earnings ratio of 24.86, the valuation of UNC can be described as rather expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of UNC indicates a slightly more expensive valuation: UNC is more expensive than 61.11% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.94, UNC is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.83 | ||
| Fwd PE | 24.86 |
4.2 Price Multiples
- 62.96% of the companies in the same industry are cheaper than UNC, based on the Enterprise Value to EBITDA ratio.
- UNC's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.97 | ||
| EV/EBITDA | 20.44 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- UNC has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as UNC's earnings are expected to grow with 38.91% in the coming years.
PEG (NY)0.66
PEG (5Y)N/A
EPS Next 2Y43.7%
EPS Next 3Y38.91%
5. Dividend
5.1 Amount
- UNC has a yearly dividend return of 0.37%, which is pretty low.
- Compared to an average industry Dividend Yield of 1.59, UNC has a dividend in line with its industry peers.
- With a Dividend Yield of 0.37, UNC pays less dividend than the S&P500 average, which is at 1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
5.2 History
- The dividend of UNC has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr YearsN/A
Div Non Decr YearsN/A
5.3 Sustainability
- UNC pays out 19.82% of its income as dividend. This is a sustainable payout ratio.
- UNC's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
FRA:UNC (1/20/2026, 7:00:00 PM)
255.7
-3.9 (-1.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners41.62%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap49.74B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts76
Price Target264.26 (3.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.29%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.55%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.83 | ||
| Fwd PE | 24.86 | ||
| P/S | 7.26 | ||
| P/FCF | 41.97 | ||
| P/OCF | 31.56 | ||
| P/B | 5.14 | ||
| P/tB | 45.76 | ||
| EV/EBITDA | 20.44 |
EPS(TTM)6.42
EY2.51%
EPS(NY)10.28
Fwd EY4.02%
FCF(TTM)6.09
FCFY2.38%
OCF(TTM)8.1
OCFY3.17%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.66
PEG (5Y)N/A
Graham Number84.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROCE | 13.73% | ||
| ROIC | 11.63% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 58.2% | ||
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% | ||
| FCFM | 17.3% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 1.15 | ||
| Cap/Depr | 61.48% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 16.4 | ||
| Cash Conversion | 64.17% | ||
| Profit Quality | 88.96% | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z | 5.42 |
F-Score9
WACC7.76%
ROIC/WACC1.5
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y28.44%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year25.37%
Revenue Next 2Y19.85%
Revenue Next 3Y17.72%
Revenue Next 5Y15.09%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year162.81%
EBIT Next 3Y59.8%
EBIT Next 5Y40.91%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%
UCB SA / UNC.DE FAQ
Can you provide the ChartMill fundamental rating for UCB SA?
ChartMill assigns a fundamental rating of 6 / 10 to UNC.DE.
What is the valuation status of UCB SA (UNC.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to UCB SA (UNC.DE). This can be considered as Overvalued.
Can you provide the profitability details for UCB SA?
UCB SA (UNC.DE) has a profitability rating of 6 / 10.
What is the valuation of UCB SA based on its PE and PB ratios?
The Price/Earnings (PE) ratio for UCB SA (UNC.DE) is 39.83 and the Price/Book (PB) ratio is 5.14.
Can you provide the financial health for UNC stock?
The financial health rating of UCB SA (UNC.DE) is 6 / 10.